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Abstract: This paper presents a review of the importance and role of precision medicine and molecular imaging 
technologies in cancer diagnosis with therapeutics and diagnostics purposes. Precision medicine is progressively 
becoming a hot topic in all disciplines related to biomedical investigation and has the capacity to become the para-
digm for clinical practice. The future of medicine lies in early diagnosis and individually appropriate treatments, a 
concept that has been named precision medicine, i.e. delivering the right treatment to the right patient at the right 
time. Molecular imaging is quickly being recognized as a tool with the potential to ameliorate every aspect of cancer 
treatment. On the other hand, emerging high-throughput technologies such as omics techniques and systems ap-
proaches have generated a paradigm shift for biological systems in advanced life science research. In this review, 
we describe the precision medicine, difference between precision medicine and personalized medicine, precision 
medicine initiative, systems biology/medicine approaches (such as genomics, radiogenomics, transcriptomics, pro-
teomics, and metabolomics), P4 medicine, relationship between systems biology/medicine approaches and preci-
sion medicine, and molecular imaging modalities and their utility in cancer treatment and diagnosis. Accordingly, 
the precision medicine and molecular imaging will enable us to accelerate and improve cancer management in 
future medicine. 
Keywords: Precision medicine, molecular imaging, precision medicine initiative, systems biology, metabolomics-
based systems medicine, cancer theranostics, radio-omics, P4 medicine
Introduction
President Obama announced in his State of 
the Union Address on January 20, 2015, “I’m 
launching a new Precision Medicine Initiative to 
bring us closer to curing diseases like cancer 
and diabetes-and to give all of us access to the 
personalized information we need to keep our-
selves and our families healthier” [1, 2]. Now 
the President has declared a research initiative 
that aims to accelerate progress toward a new 
age of precision medicine [1]. Precision (or per-
sonalized) medicine is being strongly supported 
as a solution to selectively target cancer cells 
and minimize damage to normal tissue [3]. The 
goal of this initiative is to acquire momentum of 
precision medicine [1]. It also aims to identify 
diagnostic and treatment models whose cen-
tral focus is on the individual variability of dis-
ease presentation [4]. As an inestimable tool in 
precision medicine, theranostics, which is a 
portmanteau term of “therapeutics” and “diag-
nostics”, was coined by John Funkhouser in 
2002. It can be defined as a diagnostic method-
ology for individually tailored therapeutic inter-
vention, and it personalizes healthcare practic-
es to an individual patient by removing inessen-
tial treatments for whom a standard therapy is 
not suitable and/or by optimizing a therapeutic 
plan for a particular patient [5]. The rapid 
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growth of precision medicine requires dedicat-
ed future leaders with a strong foundation in 
advanced genomic medicine, including mo- 
lecular diagnostic techniques such as next 
generation sequencing and whole genome/
exome sequencing interpretation. These lead-
ers should integrate personalized medicine into 
healthcare, and they must attain many addi-
tional management and teaching skills [6]. The 
electronic medical records (EMRs) and genom-
ic research effort work to advance personalized 
and precision medicine. In fact, the eMERGE 
network launched in 2007 is an NIH-funded 
consortium devoted to genomic discovery and 
implementation investigation by leveraging bio-
repositories connected to EMRs [7]. The preci-
sion medicine requires information technology 
(IT) infrastructure for the storage, maintenance, 
and transfer of large amounts of individual 
genomic data. With such a biobank IT, the 
researchers enable the management of genetic 
data for individual patients and other research 
[8]. The largest precision medicine project in 
Germany was launched in 2013, entitled the 
German National Cohort (GNC). This project is a 
nationwide, long-term study with an overall 
duration of 25-30 years and a €210 million 
budget for the first 10 years. Despite these 
projects, precision medicine in Germany is still 
significantly smaller than in the United States 
[9]. 
Molecular imaging is quickly acquiring recogni-
tion as a tool that has the capacity to improve 
every aspect of cancer treatments. Molecular 
imaging in oncology has been described as in 
vivo characterization and the measurement of 
key biomolecules and molecularly based events 
that are fundamental to the malignant state 
[10]. While molecular imaging is defined by the 
Society of Nuclear Medicine as the “visualiza-
tion, characterization, and measurement of bio-
logical processes at the molecular and cellular 
levels in humans and other living systems” [11], 
the burgeoning demand among physicians, 
patients, and communities for personalized 
care is increasing the importance of molecular 
imaging and forming the development of bio-
medical imaging as a whole [10]. Molecular 
imaging is developing to include a variety of 
imaging techniques to enable in vivo monitor-
ing of cellular and molecular processes [11]. 
Although molecular imaging has existed for 
decades, the rapid progress of molecular and 
cell biology, imaging technology, and imaging 
probe evolvement have highly raised its power 
and potential. Essential to the development 
and translation of molecular imaging is interdis-
ciplinary collaboration across many fields, 
including radiology, nuclear medicine, pharma-
cology, chemistry, molecular and cell biology, 
physics, mathematics, and engineering. In fact, 
these include positron emission tomography 
(PET), single photon emission computed to- 
mography (SPECT), computed tomography (CT), 
MRI, MRSI, ultrasound, and optical imaging 
[10]. Hence, imaging techniques and system 
biology approaches can be applied as two high-
throughput methods to cancer therapy and 
diagnosis in clinical experiments. 
Cancer is one of the widespread causes of 
death all over the world. Cancer research has 
focused on the identification of molecular dif-
ferences between cancerous and healthy cells 
[12]. There is much evidence that the interac-
tion and network between genes and proteins 
plays an important role in the research of can-
cer molecular mechanisms. It is essential and 
significant to present a new initiative of preci-
sion medicine in cancer investigation by inte-
grating systems biology, clinical science, omics 
technology, bioinformatics, and mathematical 
science to improve diagnosis, therapies, and 
prognosis of diseases [13]. Cancer is disease 
established on the malfunction of system char-
acteristics in biology. Therefore, it has been 
recognized as a systems biology disease [12]. 
Advances in science and technology have pro-
vided approaches toward the diagnosis, thera-
pies, and prognosis of cancer such as molecu-
lar imaging and systems biology as new target-
ed methods in clinical science. Systems biology 
has appeared during the two recent decades 
as a powerful new pattern for investigation in 
life science [14]. Our understanding of cancer 
initiation and progress has been furthered by 
means of high-throughput discovery technolo-
gies, such as next generation sequencing 
and the core omics including genomics, radi-
ogenomics, transcriptomics, proteomics, and 
metabolomics [15]. Indeed, those are systems 
biology approaches for better comprehending 
of cancer systems biology. This review’s pur-
pose is to highlight the role and importance of 
precision medicine and molecular imaging 
technologies accompanying systems biology/
medicine approaches to cancer therapeutics 
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and diagnosis to create new targeted approach-
es in future medicine.
Precision medicine
According to the National Institutes of Health 
(NIH), precision medicine is “an emerging 
approach for disease treatment and prevention 
that takes into account individual variability in 
genes, environment, and lifestyle for each per-
son” [2, 16, 17]. This approach will permit phy-
sicians and investigators to predict more pre-
cisely which treatment and prevention strate-
gies for a special disease will work in which 
groups of people. It is in conflict to a “one-size-
fits-all” approach in which disease treatment 
and prevention strategies are developed for the 
average person, with less consideration for the 
differences between individuals. Although the 
term “precision medicine” is relatively new, the 
concept has been a part of healthcare for many 
years. For instance, a person who requires a 
blood transfusion is not given blood from a ran-
domly selected donor; instead, the donor’s 
blood type is matched to the recipient to 
decrease the risk of complications [1, 2]. 
Although examples can be found in several 
areas of medicine, the role of precision medi-
cine in day-to-day healthcare is relatively limit-
ed. Scientists hope that this approach will 
expand to many areas of health in the coming 
years [16]. Indeed, precision medicine is now 
widely utilized only in oncology [4], particularly 
for treatment the of melanoma, metastatic 
lung, breast, and brain cancer and leukemia 
[18]. Radioiodine theranostics is a typical 
example of precision medicine and has been 
utilized widely for the management of differen-
tiated thyroid cancer [5]. Generally, precision 
medicine has not yet become a medical stan-
dard for many conditions in spite of its high 
expectations in the United States, Germany, 
and other countries [9]. 
Difference between precision medicine and 
personalized medicine
Between the terms “precision medicine” and 
“personalized medicine”, there is a lot of over-
lap. According to the National Research Council 
(United States), “personalized medicine” is an 
older term with a meaning similar to “precision 
medicine”. There was concern that the term 
“personalized” could be misconceived to imply 
that treatments and preventions are being 
advanced uniquely for each individual; in preci-
sion medicine, the focus is on identifying which 
approaches will be effective for which patients 
based on genetic, environmental, and lifestyle 
factors [2, 9, 19]. The Council therefore pre-
ferred the term “precision medicine” to “per-
sonalized medicine”. However, some people 
still utilize the two terms interchangeably [16].
Precision medicine initiative
In early 2015, President Obama announced a 
strong conviction that science and investiga-
tion offer great potential for focusing on bring-
ing precision medicine to many facets of health-
care [1, 9, 20]. The President’s budget for fiscal 
year 2016 comprised of $216 million in funding 
for the initiatives of the NIH, the National 
Cancer Institute (NCI, the NIH institute focused 
on cancer research), and the Food and Drug 
Administration (FDA) [9]. The Precision Medicine 
Initiative has both short-term and long-term 
purposes. The short-term objectives include 
enlarging precision medicine in the field of can-
cer research. Investigators at the NCI hope to 
utilize this approach to find novel, more effec-
tive cares for different types of cancer based 
on increased knowledge of the biology and 
genetics of the disease. The long-term objec-
tives of the Precision Medicine Initiative focus 
on bringing precision medicine to all aspects of 
health and healthcare on a large scale as well 
as generate knowledge applicable to the whole 
range of health and disease [1]. For this goal, 
the NIH schemes to start a study including a 
group (cohort) of at least one million volunteers 
from around the United States. Participants will 
provide genetic data, biological samples, life-
style, environment, and other information 
about their health. This data will be utilized by 
investigators to examine a large range of dis-
eases, with the aims of better predicting dis-
ease risk, comprehending how diseases hap-
pen, and finding improved diagnosis and treat-
ment strategies [16].
Systems biology as an efficient tool in preci-
sion medicine
The expression “systems biology” has appeared 
during recent years to explain the frontier of 
interdisciplinary investigations in biology [21]. 
The modern biology is supported by the prog-
ress in high-throughput experimental tech-
niques such as genomics, transcriptomics, pro-
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teomics, metabolomics, phenomics, and other 
omics technologies that may generate “big 
data science”. Systems biology has been 
described as the study of biological compo-
nents and their interactions using models and/
or networks to integrate genes, metabolites, 
proteins, regulatory elements and other bio- 
logical components via high-throughput tech-
nologies such as DNA-microarray, Fluorescen- 
ce microscopy, Illumina sequencer, GC-MS, 
LC-MS, MALDI-TOF, HPLC, FT-IR, mass spec-
trometry, HPLC-MS, NMR, and so on [22, 23]. 
Through systems biology, we can find out more 
puzzling images regarding the fundamental 
components of biology including the genome, 
transcriptome, proteome, metabolome, mem-
brane systems, organelles [24, 25]. The big 
data biology, network biology, and other new 
branches of modern biology have emerged as a 
result of the combination of versatile knowl-
edge (Figure 1). For instance, understanding of 
systems-level of the cell or cellular components 
and subprocesses will be facilitated by network 
biology. The aim of systems biology is to com-
Figure 1. A general hierarchi-
cal diagram of the systems 
biology approaches integrated 
to the molecular imaging tech-
niques toward diagnosis and 
prognosis a typical cancer 
disease. 
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prehend the functions and mechanisms in 
the different levels of organisms or cells [26]. 
Today, systems biology is encountering the 
challenges of analyzing huge biological net-
works and big molecular biological data.
Systems approaches
It is necessary to integrate experimental and 
computational research in order to understand 
complex biological systems. In other words, it is 
a systems biology approach [27]. Nowadays, 
the holistic systems biology approaches have 
created a new outlook in biology, medicine, and 
pharmacological sciences [28, 29]. Systems 
biology has provided the base for encoding the 
structure, variation, and function of the human 
genome and relating them to health and dis-
ease states by high-throughput technologies 
for DNA sequencing and for analyses of tran-
scriptomes, proteomes, and metabolomes 
[29]. Many biological processes have already 
applied omics approaches to lead a large num-
ber of genes potentially included in correspond-
ing modules. Development and implementa-
tion of computational methods was an impor-
tant step of progress by which genes or proteins 
that conduct similarly under different experi-
mental situations [30]. In this section, we dis-
cuss on the principal “omics” techniques 
including genomics, transcriptomics, pro-
teomics, and metabolomics as the most fre-
quently approaches applied in systems medi-
cine research. An overview of the omics tech-
nologies for systems medicine and precision 
medicine has also been presented (Table 1).
Genomics and transcriptomics
Evolution in high-throughput technologies has 
produced a paradigm shift for biological sys-
tems in advanced life science investigations. 
The systems biology by means of methodically 
organizing the genomics, functional genomics, 
and proteomics data attempts to provide a sys-
tems-level comprehension of the biological 
phenomena [31]. In 1986, the term “genomics” 
was coined by Thomas Roderick for first time. 
Genomics expression was quickly applied as 
the novel journal name intended to sustain the 
new areas and discipline of genome mapping 
and sequencing [21, 32]. Indeed, this was a big 
and fantastic transformation in molecular biol-
ogy through the evolution of dramatically effi-
cient approaches for DNA sequencing [33]. 
Genomics is the branch of science that studies 
the genome, or the genetic material or blue 
print of a plant, animal, human, microorgan-
isms, and/or other species in order to under-
stand the functions, gene interactions, and 
regulation of gene networks with each other 
and the environment [34]. Nevertheless, the 
focus of genomics research is mostly on the 
investigation of sequencing (sequence genom-
ics), functions (functional genomics), struc-
tures, and interactions of genes. An example of 
a huge international genomics project was the 
Human Genome Project that was successfully 
completed in 2003 [21]. One of the first omics 
technologies that had thereafter developed 
was transcriptomics [35]. Transcriptomics is 
defined as the study of transcriptome under 
particular circumstances or in a certain cell by 
high-throughput technologies such as RNA-seq 
and microarray analysis [36]. The most impor-
tant purposes of transcriptomics are: to make 
an itemized list of all species’ transcripts, 
including mRNAs, non-coding RNAs, and small 
RNAs; to appoint the transcriptional structure 
of genes in terms of their beginning sites, 5’ 
and 3’ ends, splicing models, and other post-
transcriptional alterations; and to quantify the 
modifying expression levels of each transcript 
during evolution and under various situations. 
Table 1. An overview of the common omics techniques for systems medicine and precision medicine
Technique Molecules of interest Description
Temporal 
variance
Affect by 
disease 
status
High-throughput instruments
Genomics DNA Evaluation of variability in DNA  
sequence in the genome
None No Illumina sequencing, Pyrosequencer 
(GS-FLX Titanium), Roche 454 [37, 115]
Transcriptomics RNA Evaluation of variability in composition 
and abundance of the transcriptome
High Yes Affx arrays (Illumina sequencing, Roche 
454) [37, 115]
Proteomics Protein Evaluation of variability in composition 
and abundance of the proteome
High Yes MS, 2DE, iTRAQ [47, 115, 116]
Metabolomics Small molecules 
(metabolites)
Evaluation of variability in composition 
and abundance of the metabolome
High Yes NMR, DE-NMR, LC-MS, GC-MS, MALDI, 
MS [47, 115]
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In order to conclude and quantify the trans- 
criptome, various state of the art technologies 
have been created such as hybridization or 
sequence-based approaches [37].
Radiogenomics
Radiogenomics is the newest member of omics 
family. The concept of radiogenomics is the 
study of the correlation between cancer imag-
ing features and gene expression (Imaging 
Genomics) and genotypic variations observed 
in response to radiation therapy (Radiation 
Genomics) [38]. The combination of imaging 
tools with molecular techniques (such as func-
tional genomics assays) offers the potential for 
the quick clinical translation of powerful high-
throughput technology [39]. Radiogenomics 
may create imaging biomarkers that can recog-
nize the genomics of a disease, particularly 
cancer, without the use of a biopsy [40]. 
Numerous techniques are applied to reveal cor-
relations between MRI, CT, and PET imaging 
features and the genomics of disease (such as 
large-scale MRI microRNA-mRNA correlative 
study in glioblastoma, liver cancer genome 
from non-invasive imaging features, and link 
image characteristics of non-small cell lung 
nodules in CT scans) to predict survival using 
gene expression data [39]. In addition, func-
tional CT in oncology and cardiovascular imag-
ing is a key player in the age of precision medi-
cine and radiogenomics [41].
Proteomics
Proteomics, the study of proteomes on a large 
scale, promises to transform biology and medi-
cine [42, 43]. The study of proteomes in the 
large scale is defined as proteomics. A pro-
teome is defined as the set of proteins that is 
generated in a system, organism, or other bio-
logical entity. For example, we can refer to the 
proteome of an organ, such as the liver, or of a 
species, such as Homo sapiens. The proteome 
changes from cell to cell at any given time; thus, 
it is not constant [44]. The term “complete pro-
teome” is applied in the field of mass spectrom-
etry (MS)-based proteomics, pointing toward 
the presently unachieved aim realizing all the 
proteins of a given species [45]. To investigate 
proteomes, several high-throughput techniques 
have been developed, among them mass spec-
trometry (MS)-based techniques, such as tan-
dem-MS, and gel-based techniques, such as 
differential in-gel electrophoresis, which are 
the most utilized in proteomics. Via these high-
performance devices, we can produce enor-
mous amounts of data. Therefore, we require 
databases for registering, storing, and main-
taining these huge amounts of data so that 
investigators can create links between their 
outcomes and the available knowledge [44, 
46].
Metabolomics 
Metabolomics enables the integration and 
merging of biological data from different levels, 
revealing communication and connectivity 
inside a system as a key for precision medicine 
and phenotyping [47]. Metabolomics is an 
omics technique in systems medicine that is 
used in the global quantitative evaluation of 
endogenous metabolites in a biological system 
[48]. Metabolomics is progressing, with power-
ful technology enabling the assay and detec-
tion of the huge numbers of metabolites in tis-
sues and biofluids [49, 50]. Currently, metabo-
lomics research can provide applicable and 
useful information regarding health and dis-
ease status. Metabolomics techniques such as 
NMR and mass spectroscopy are applied to 
detect and treat various cancers [49]. In recent 
years, the universal metabolic profiling of dis-
eases has become feasible via the use of high-
throughput analytical devices [51]. 
Systems approaches in cancer management
At present, researchers utilize a number of 
complementary omics techniques to investi-
gate an extensive range of diseases, including 
cancer [52]. Major attempts have been made 
to apply systems biology approaches to oncol-
ogy [22, 53, 54]. High-throughput and sophisti-
cated omics technologies, such as genomics, 
radiogenomics, proteomics, and metabolo-
mics, have provided a foundation for a new 
kind of oncological investigation [55]. These 
advances in experimental systems biology, 
along with novel analytical techniques and 
quantitative imaging software tools, are helping 
to create a more perfect image of many can-
cers connected to signaling routes [22, 55, 56]. 
Recently, metabolomics approaches have been 
applied as an important tool for detection, 
prognosis, biomarker discovery, and the design 
of therapeutics [57]. Denkert et al. utilized gas 
chromatography/time of flight mass spectrom-
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etry (GC-TOF-MS) to analyze ovarian cancer 
metabolism in both invasive carcinomas and 
borderline tumors [58, 59]. In recent studies, 
Japanese investigators have diagnosed gastro-
enterological cancer via the metabolomic dis-
covery of a pancreatic cancer biomarker [60]. 
Wikoff et al. have succeeded in discovering 
blood-based biomarkers relevant to lung can-
cer screening and early detection via metabolo-
mic analysis approaches [61]. In the field of 
thyroid cancer investigation, there are abun-
dant studies demonstrating the successful 
application of omics technologies, such as 
genomics, transcriptomics, and proteomics. 
Metabolomics tools have been utilized in iden-
tifying a great number of metabolites in thyroid 
cancer in recent years [62]. Systems biology/
medicine approaches also improve the under-
standing, treatment, and clinical management 
of neuroendocrine prostate cancer [63]. A 
schematic illustration of the metabolomics-
based systems medicine and molecular imag-
ing tools used in cancer diagnosis studies is 
presented in Figure 2.
P4 medicine
Medicine is now experiencing a major revolu-
tion that will change the current healthcare sys-
tem from reactive to proactive in every way [19, 
39, 64]. In fact, systems biology and the digital 
revolution are transforming healthcare into a 
proactive type of P4 medicine, meaning that it 
is predictive, preventive, personalized, and par-
ticipatory [64, 65]. However, the term of “per-
sonalized medicine” is an expression for a 
revolution in medicine that will be predictive, 
universal, and integrative approach to biology. 
More specifically, systems medicine is a sys-
tems approach to health and disease. Systems 
biology provides the strategies, instruments, 
and computational and analytical capabilities 
needed to analyze huge amounts of informa-
tion [19, 29, 69]. These strategies and tools 
can be utilized in order to combat diseases 
[70]. Here, we will debate precision medicine in 
the form of molecular imaging: 1) Personalized: 
P4 medicine will be ‘personalized’ because it 
will be established based on the genetic and 
epigenetic data of each person. Individualized 
or precision medicine may assist in data mining 
regarding quantitative biology and anatomy, in 
targeted imaging/targeted therapy, and also in 
the real-time monitoring of treatment response. 
Molecular imaging can provide special molecu-
lar profiles and assist in selecting the most effi-
cient treatment with the minimum toxicity on a 
personalized basis [39, 71-73]. Imaging agents 
that have both diagnostic and therapeutic abili-
ties, or ‘theragnostics’, will probably be more 
cost-effective and popular [39, 74]. The great 
advantage of molecular imaging in personal-
ized medicine is its ability to merge physiologic 
and metabolic data with clinical phenotypes 
and provide inestimable information concern-
ing treatments. 2) Predictive: generally, one 
human being differs from another by less than 
1% in terms of their hereditary structure. These 
genetic differences cause physical differences, 
such as the tendency to develop various dis-
eases [39, 75]. Medicine will be ‘predictive’ 
because this individual data will allow physi-
cians to estimate the risk of particular diseases 
Figure 2. A schematic illustration of metabolomics-based systems medicine 
and molecular imaging tools into cancer diagnosis studies. 
preventive, personalized, and 
participatory. This aspect of 
medicine was nominated P4 
medicine [19, 66]. P4 medi-
cine comprises of predictive, 
preventive, personalized, and 
participatory medicine [2, 64, 
65, 67]. The essence of P4 
medicine is the quantification 
of healthiness or wellness 
and the clarification of dis-
ease [68]. P4 medicine will 1) 
create better healthcare, 2) 
decrease the cost of health-
care, and 3) motivate innova-
tion and the creation of new 
corporations [68]. Meanwhile, 
systems biology is a holistic, 
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in each person [39, 73]. Imaging modalities 
will play a meaningful role as non-invasive 
screening methods that are both sensitive 
and accurate predictors of disease [39, 76]. 
Investigations have shown that only PET influ-
enced management decisions in 38% of cancer 
cases [39, 77]. 3) Preventive: medicine will be 
‘preventive’ because the prediction of risk will 
permit the utilization of prophylactic proce-
dures (way of life or therapeutic) to reduce this 
risk. Molecular/genetic screening and interven-
tion (often directed by imaging) are the most 
effective methods of disease management [39, 
73]. Theragnostic agents can also be used. 4) 
Participatory: medicine will be ‘participatory’ 
due to the fact that most of these prophylactic 
manipulations will require the participation of 
the patient. This consists of a domain of partici-
patory activities, such data sharing, training 
[29, 64]. Furthermore, the biology and disease 
are unbelievable complicated [19, 79]. The pre-
cision medicine has extremely developed by 
advance of high-throughput technologies and 
systems approaches. Indeed, the field of preci-
sion medicine is changing the paradigm of 
future health care from conventional medicine 
practice (diagnosis and treatment) to predictive 
and preventative medicine and personalized 
health supervising [80, 81]. Progress of high-
throughput technologies like high-throughput 
sequencing and mass spectrometry has made 
capable researchers, scientists and clinicians 
to study genomes, transcriptomes, proteomes, 
metabolomes, and other omics data in unex-
ampled detail. The integrated ‘omics’ data can 
be led to a universal profiling of health and dis-
ease, and provide novel approaches for P4 
medicine and health monitoring [64, 82-85]. 
patients and physicians, and 
also counseling patients re- 
garding individual options con-
nected to sickness and well-
being. The increasing utiliza-
tion of social networks by 
patients, and also the activi-
ties of patients’ associations, 
are examples of participatory 
actions [39, 73]. It is also 
anticipated that “technology 
singularity” and “exponential 
medicine”, as new approach-
es, will shift the paradigm of 
medical philosophy and gener-
ate a considerable influence 
on the healthcare system and 
patient-physician relationship 
[78]. Here, a schematic repre-
sentation of the procedure for 
precision medicine (predic-
tive, preventive, personalized 
and participatory) and two 
principal objectives of the pre-
cision medicine are demon-
strated (Figure 3).
Linkage of the systems ap-
proaches and precision medi-
cine
Systems biology is growing 
quickly, and the term “preci-
sion medicine” has also 
emerged as a significant revo-
lution in modern medicine 
Figure 3. A schematic representation of the procedure of precision medicine 
(predictive, preventive, personalized and participatory) and two principal ob-
jectives of precision medicine as future of medicine comprising: 1) Quantify-
ing wellness, 2) Demystifying disease. 
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The power of systems biology in personalized 
medicine lies in disease risk estimation, per-
sonalized health monitoring and preventative 
medicine more significantly and it is not only 
for disease mechanism explanation. Systems 
biology provides forceful tools to supervise 
molecular profiles and discern delicate chang-
es that can demonstrate network disturbance. 
Physicians and pathologists are energetically 
combining systems biology and medicine tools 
to attain molecular disease diagnosis [86, 87]. 
Regarding to undergoing period in medicine, we 
require contributing between systems biology 
and molecular imaging in the future medicine. 
Therefore, we will be able to estimate and 
monitor of personalized disease risk and health 
care with applying integrative omics techni- 
ques and molecular imaging technologies. We 
may connect systems biology and systems 
medicine via the implementation of omics tech-
nologies, which are the most efficient tools 
available in modern biology and precision medi-
cine for disease diagnosis (Figure 4). 
Relationship of imaging and systems ap-
proaches in precision medicine
Molecular imaging and systems biology 
approaches play an important role in develop-
gy. Recently, the radiogenomics/radiomics and 
radiotranscriptomics technology has emerged 
as a new area of omics in molecular imaging 
field [36, 88]. In fact, novel imaging strategies 
in the era of precision medicine require the 
focus on improved characterization of disease 
by phenotyping disease specific imaging char-
acteristics within the concept of genetic patient 
information in order to non-invasively identify 
patient subpopulations that benefit from simi-
lar treatments or vice versa [41]. On the other 
side, radiology requires “Big-Data” analysis 
that is feasible by bioinformatics and systems 
biology approaches. Since, the radiogenomics 
generates large amount of genotyping data by 
imaging from gene expression profile and geno-
typing variation [88]. The precision medicine 
requires the individual genetic data to assess 
many characteristics in cancer detection and 
diagnosis by researchers. Molecular imaging 
contributes with systems biology methods 
(such as computational and modeling) to ana-
lyze and interpret the image results. Indeed, 
the synergy of imaging, genomics, transcrip-
tomics and other omics data can be construct-
ed a bridge between systems biology approach 
and molecular imaging leads to precision 
medicine goals [36, 92-94] (Figure 5). These 
progressions provide opportunities for the 
Figure 4. The components that will permit to precision medicine for discover-
ing the biological complexity. These emerging technologies such as systems 
biology approaches and molecular imaging techniques will enable the imple-
mentation of precision medicine.  
ing precision medicine in the 
cancer management [88]. The 
evolvement of high-through-
put technologies able to com-
prehensively evaluate DNA, 
RNA, protein, and metabolites 
in tumors management [89]. 
High-throughput experiments 
such as genomics, radioge-
nomics, transcriptomics, ra- 
diotranscriptomics, proteomi- 
cs, radioproteomics, metabo-
lomics and radiometabolo-
mics provide a basis for new 
kinds of oncology investiga-
tion. These progresses in sys-
tems biology linked with mod-
ern analytical and also quanti-
tative imaging software tools 
are assisting to create a more 
complete picture of many 
cancer related signaling path-
ways and personalized can- 
cer management [22, 90, 91]. 
The omics technologies are 
major basis of systems biolo-
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advancement of personalized oncology in 
which cancer detection, diagnosis and therapy 
are tailored to each individual’s molecular 
profile.
Figure 5. From Radiogenomics to 
Radiometabolomics. We present 
a transition from the integration 
of systems biology with molecular 
imaging techniques to precision 
medicine. 
Figure 6. A typical representative of the PET/MRI imaging benefits in Precision medicine cancer care. Staging PET/
MRI scan of a 56-year-old woman with ovarian cancer. The MRI images (A and B) show multiple lesions abutting the 
liver posteriorly (long arrow), involving the porta hepatis (short arrow) and seeding the peritoneum (arrowheads). A 
round, well defined lesion with same features is also visualized in segment IV of the liver (dotted arrow). On PET/
MRI images (C and D) the lesions earlier described, and others not so evident, are depicted by high FDG uptake 
confirming their malignant nature. Maximum intensity projection of the whole body (E) reveals several lesions both 
in the chest and abdomen. Reproduced from [117].
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Table 2. Comparison of emerging molecular imaging technologies for precision medicine
Key UtilizationImaging Agents and Molecular ProbesDepth of Penetration
Imaging 
TimeSpatial ResolutionImaging Modalities
Visualization of cell structuresFluorescent proteins, dyes, rhodamine 
amide, quantum dots
-Secs15-1000 nmMulti-photon Microscopy
Mapping cell surfaceIntermolecular forces-Mins10-20 nmAtomic Force Microscopy
Discerning protein structureCyrofixation-Secs0.2-3 nmElectron Microscopy
Vascular imagingMicrobubbles, nanoparticlesmm-cmSecs50 μm, 0.01-0.1 mm
1-2 mm
Superficial applications
Deeper applications
Ultrasound (US)
Lung and bone tumor imagingIodineLimitlessMins12-50 μm, 50-200 μm
0.5-1 mm
Preclinical
Clinical
CT
Anatomical imaging
Functional
Gadolinium, dysprosium, iron oxide 
particles
LimitlessMins-Hrs4-100 μm, 25-100 μm
~1 mm
Preclinical
Clinical
MRI
Functional imaging of brain activityOxygenated hemoglobin
(HbO2) deoxygenated hemoglobin (Hb)
-Secs-Mins~1 nmfMRI
Detection of metabolitesN-acetylaspartate (NAA), creatine, choline, 
citrate
-Secs~2 nmMRS
Metabolic imagingFluorodeoxyglucose (FDG), 18F, 11C, 15OLimitlessMins1-2 mm
5-7 mm
Preclinical
Clinical
PET
Cardiovascular imaging, diagnosis 
of bone metastasis
Tc-99m, In-111, I-131-labeled compounds, 
Ga-67, Tl-201, Peptide
LimitlessMins1-2 mm
8-10 mm
Preclinical
Clinical
SPECT
characterization of cancerPeptide, integrins, matrix metallo-proteinas-
es, caspases
< 1 cmSecs-Mins2-3 mmOptical fluorescence imaging (OFI)
Gene expression, cell & bacterial 
tracking
Luciferins, coelenterazines, luminal, 
Peptide
1-2 cmSecs-Mins3-5 mmOptical bioluminecence imaging (OBI)
Oligonucleotide targetingEGFR-SERS, EGFR affibody-gold-silica 
nanoparticles
~5 mmMin-daysmmSurface-enhanced  raman scattering 
(SERS) imaging
Functional imaging of blood 
oxygenation
EGFR Antibody-gold nanoparticles [Nle4, 
d-Phe7]- -melanocyte-stimulating hormone-
gold, hormone-gold nanocages
6 mm to 5 cmSecs-Mins~10 μm to 1 mmPhotoacoustic imaging (PAI)
In development (endoscopy, skin)Photoproteins, fluorochromes< 400-800 μm, 
~700 μm
Secs-days1 μmIntravital microscopy (IVM)
Rapid screening of molecular 
events in surface-based disease
Photoproteins, fluorochromes< 1 cmSecs-Mins1 mmFluorescence reflectance imaging (FRI)
Quantitative imaging of targeted or 
“smart” fluorochrome reporters
Near Infrared, fluorochromes2-3 cmMins1 mmFluorescence mediated tomography (FMT)
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Molecular imaging technologies 
In total, Imaging is an essential part in research, 
trials and practice in field of oncology. There 
has been a vast growth in the number and type 
of imaging technologies and their uses in past 
three decades, although some issues remain. 
At present, molecular imaging is an emerging 
subject that integrates advanced imaging tech-
nology with cellular and molecular biology [95]. 
The molecular imaging term can be defined as 
visual representation, characterization, mea-
surement and quantification of biological pro-
cesses at the molecular, cellular and sub-cellu-
lar within entire living organisms using specific 
and appropriate imaging probes [11, 96, 97]. 
Molecular imaging technologies play a crucial 
role in earlier detection, precise diagnosis of 
diseases like cancerous tumors, and drug 
development and discovery [95, 98-100] 
Figure 7. Schematic overview of precision medicine strategies exploiting the tumor microenvironment. Reproduced 
from [3] with permission of John Wiley and Sons License.
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(Figure 6). Molecular imaging needs to high 
resolution and high sensitive tools to detect 
and realize specific imaging agents that con-
nect the imaging signal with molecular occur-
rence [95, 101]. There are copious classes of 
molecular imaging agents comprising small 
molecules, peptides, aptamers, high-molecu-
lar-weight antibodies, engineered protein frag-
ments, and various nanoparticles [102]. At 
present, only some of evolving of molecular 
imaging technologies is used in clinical and pre-
clinical stage e.g.  Positron-emission tomogra-
phy (PET), single-photon-emission CT (SPECT), 
fluorescence reflectance imaging, fluores-
cence-mediated tomography (FMT), fibre-optic 
microscopy, optical frequency-domain imaging, 
bioluminescence imaging, laser-scanning con-
focal microscopy and multiphoton microscopy 
[95, 98, 102-105]. Table 2 summarizes the 
characterizations and features of the some 
molecular imaging modalities with extraction 
and adaption of available references and litera-
tures that have been published by outstanding 
scientists in the molecular imaging field [22, 
96, 102, 105-108]. Molecular imaging modali-
ties, imaging agents, and applications are well 
written by James ML and et al. [102]. 
Molecular imaging in cancer management
Modern molecular imaging technologies have 
the potential to meaningfully increase the diag-
nostic and therapeutic approaches for cancer 
treatment [109]. Molecular imaging based per-
sonalized therapy has been a fascinating con-
cept for individualized therapeutic strategy, 
which is able to obtain the highest efficacy and 
decrease adverse effects in specific patients 
[5, 110-112]. Applications of molecular imag-
ing can be assisted to detect malignant cells at 
cellular levels in the early stage formation of 
cancer [10, 113]. Molecular imaging tech-
niques also may consider tumor characteriza-
tion and cancer diagnosis without any invasive 
operations like biopsy or even surgery [109, 
114]. Nevertheless, molecular imaging modali-
ties and its probes are being evolved and 
enhanced more and more for realizing types of 
cancer in frame work of non-invasive proce-
dures (Figure 7).
Conclusion and future perspective 
Cancer is a devastating disease that modifies 
the metabolism of a cell and the encircling 
milieu. Systems biology and molecular imaging 
approaches are being employed to better com-
prehend these alterations in cancer diagnosis 
and therapy in the era of precision medicine. In 
order to successful curing of patients, early 
detection, precision staging and remove of can-
cer tissue are very important. To detect the 
cancer types, we require to precision medicine 
tools such as systems approaches (genomics, 
radiogenomics, transcriptomics, proteomics, 
and metabolomics) and molecular imaging 
techniques. Molecular imaging technologies 
have key role for enhancing cancer diagnosis 
Figure 8. An overview of the integration of radio-omics, Molecular biology information and molecular imaging data 
in precision cancer medicine. 
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and treatment by extending imaging modalities 
to a functional and cellular level as well as 
improving intraoperative imagining of diseased 
and healthy tissues for surgeons. Though, med-
icine is now undergoing a major revolution that 
will change the nature of healthcare from reac-
tive to proactive. It will increasingly transition 
to predictive, preventive personalized and 
participatory medicine (precision medicine). 
Meanwhile, ongoing technological progresses, 
particularly in the field of systems biology and 
molecular imaging, and also interdisciplinary 
cooperation with miscellaneous branches of 
science are compulsory for the implementation 
of precision medicine. These technologic 
improvements have been rapid in the imaging 
technologies such as MRI, CT, US, and imaging 
with radionuclides, fluoroscopy and bio-lumi-
nescence. In summary, “Radio-omics”, there-
fore, poses as a promising contributor to the 
precision medicine initiative and P4 medicine, 
advancement both reactive and proactive mea-
sures through disease diagnosis in pre-symp-
tomatic stages and appropriate targeting of 
therapeutic programs (Figure 8).
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